Cite
MLA Citation
Anna Vinitsky et al.. “LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG).” Neuro-oncology, vol. 24, n.d., p. i92. http://access.bl.uk/ark:/81055/vdc_100156448889.0x000027